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In order to investigate the frequency of HHV-8 in MM patients
from another geographic location, we obtained fresh bone mar-
row (BM) biopsies from Turkish patients with MM (n = 21),
monoclonal gammopathy of undetermined significance
(MGUS) (n = 2), plasmacytoma (n = 1) with BM plasma cell infil-
tration, various hematological disorders (n = 6), and five heal-
thy Turkish controls. The frequency of HHV-8 was analyzed by
polymerase chain reaction (PCR) in two independent labora-
tories in the USA and in Turkey. Using fresh BM biopsies, 17/21
MM patients were positive for HHV-8 whereas all five healthy
controls, and six patients with other hematological disorders
were negative. Two patients with MGUS, and one patient with
a solitary plasmacytoma were also negative. The data from the
two laboratories were completely concordant. Also using
primer pairs for v IRF and v IL-8R confirmed the results
observed with the KS330233 primers. Furthermore, sequence
analysis demonstrated a C3 strain pattern in the ORF26 region
which was also found in MM patients from the US. Thus, HHV-
8 is present in the majority of Turkish MM patients, and the
absence of the virus in healthy controls further supports its
role in the pathogenesis of MM. Leukemia (2001) 15, 1268–1273.
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Introduction
HHV-8 is a new member of the gamma herpesvirus family
originally discovered in tumor tissue derived from patients
with Kaposi’s sarcoma.1 The virus is known to produce homo-
logues to human cytokines such as IL-6 and IL-8R that could
potentially promote tumor cell growth.2 Recently, the virus
was identiﬁed in nonmalignant stromal cells cultured from the
bone marrow (BM) of patients with multiple myeloma (MM).3
Subsequent analysis of fresh BM biopsies and peripheral
blood mononuclear cells enriched for the dendritic markers
CD68 and CD83 also revealed HHV-8 DNA in most of these
patients.4–6 Similar cultures and samples derived from healthy
controls and patients with other hematological malignancies
only rarely showed detectable virus. These initial ﬁndings
have been conﬁrmed by other investigators within the USA
and France7,8 but refuted by other groups from the UK, France
and Sweden.9–11 These conﬂicting results may be the conse-
quence of technical problems or epidemiological differences
in the patient populations studied. Thus, in order to clarify
the role of epidemiological differences, we studied a patient
population with a different ethnic origin. For this purpose,
samples from MM cases and normal subjects living in Turkey
were selected.
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Patients and methods
Patients
Twenty-four patients with monoclonal gammopathies referred
from different geographical regions and admitted to the
Department of Hematology at Ibni Sina Hospital, Ankara Uni-
versity School of Medicine were included in the study. Sam-
pling was done at the time of diagnosis in 18 patients, and
following treatment in six patients. All patients with MM (n =
21) had an increased frequency of clonal plasma cells in the
BM except for a patient who was in remission following auto-
logous peripheral blood stem cell transplantation (PBSCT). In
addition, uninvolved marrow from a patient with a solitary
plasmacytoma, and two patients with monoclonal gammopa-
thy of undetermined signiﬁcance (MGUS) were also included
in the study. Previously treated patients (n = 6) had received
either melphalan and prednisolone or VAD but were either
refractory or had relapsed at the time of analysis.
As controls, ﬁve individuals (related donors for BM trans-
plants (n = 3) and healthy subjects following treatment of iron
deﬁciency anemia (n = 2)) were analyzed. In addition, six
patients with other hematological disorders were included in
the study: one patient each with polyclonal gammopathy,
nephrotic syndrome and monoclonal gammopathy, ITP,
CML in second chronic phase, and two patients with
non-Hodgkin’s lymphoma.
Methods
BM biopsies were obtained from the posterior iliac crest in all
subjects, transferred in RPMI 1640 medium containing 10%
DMSO, and stored in liquid nitrogen. Samples were shipped
in dry ice to the West LA VA Medical Center where molecular
studies were performed in a blinded fashion. Furthermore, 14
of the same samples were also analyzed in the Department
of Molecular Biology and Genetics at Bilkent University in a
double-blind fashion. Since the remaining 15 DNA samples
were sent to the US without a back-up aliquot they could not
be studied in Turkey.
HHV-8 detection by DNA-PCR
Extraction of nucleic acids: DNA was extracted by using
the Easy DNA kit (Invitrogen, La Jolla, CA, USA), and the con-
centration was measured by a ﬂuorometer (Hoeffer Scientiﬁc,
San Francisco, CA, USA). Concentration of the DNA was
adjusted to 50 ng/l. RNA was prepared with RNAzol (Tel-
Test, Friendswood, TX, USA) according to the manufacturer’s
instructions, and measured by a spectrophotometer.
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For detection of KS 330233 (ORF 26), a forward primer (5-
AGC CGA AAG GAT TCC ACC AT-3) and a reverse primer
(5-TCC GTG TTG TCT ACG TCC AG-3) was used. We
evaluated 200 ng of DNA (equivalent to the amount of DNA
from 30000 cells). A total of 45 cycles of PCR ampliﬁcation
was performed on each sample. The PCR mixture consisted
of Buffer-B (PCR Optimizer Kit; Invitrogen, San Diego, CA,
USA), Taq polymerase (Perkin Elmer, Norwalk, CT, USA), and
Taq antibody (Clontech, Palo Alto, CA, USA). Each PCR cycle
consisted of 1 min at 95°C, 90 s at 55°C, 2 min at 72°C, after
an initial denaturation of 5 min at 95°C. The positive control
was genomic DNA from the HHV-8-containing pleural
effusion lymphoma cell line KS-1. To evaluate whether gen-
omic DNA was intact and in adequate amounts, PCR was per-
formed for all the specimens using either beta actin primers
(Stratagene, La Jolla, CA, USA) (forward primer, 5-TGA CGG
GGT CAC CCA CAC TGT GCC CAT CTA-3; reverse primer,
5-CTA GAA GCA TTT GCG GTG GAC GAT GGA GGG-3),
or hMLH1 (human mut-L homologue 1, a DNA mismatch
repair gene) exon 14 primers (forward primer, 5-TGGTG
TCTCTAGTTCTGG-3; reverse primer, 5-CATTGTTGTAG-
TAGCTCTGC-3). Two sets of primers were used to amplify
ORF74 (vIL-8R) (forward primer, 5-CAGCACTAGGTTA
GGTTGAA-3; reverse primer, 5-GAACGGGAGGCTAGAT-
TAAA-3) to generate a 533 base pair product and ORFK9
(vIRF) (forward primer, 5-TGT GGT GGC TGC GAT AAC-3;
reverse primer, 5-TCT TCG TCT TCC CAC TCT A-3) to give
a PCR product of 147 bp. To eliminate bias in our results, the
PCR assays were performed randomly and in a blinded
fashion in both institutions. In Turkey, ORFK9 and hMLH1
primers were used for conﬁrmation. Negative controls were
either a PCR mix without DNA or with placental DNA (Sigma,
St Louis, MO, USA). Ampliﬁed PCR products (10 l) were
electrophoresed on a 1% agarose gel impregnated with ethid-
ium bromide and then photographed. In order to determine
the sensitivity of our PCR assay to detect HHV-8, plasmid con-
taining these HHV-8 primers was serially diluted with normal
human granulocyte DNA, and PCR ampliﬁcation was perfor-
med. The results showed that the sensitivity of the PCR assay
could detect approximately one to two copies of vIRF or
ORF26.12
RT-PCR
One g of total RNA was used in reverse transcription. RNA
was extracted from BM biopsies of MM and MGUS patients
as well as controls. First-strand synthesis was performed at
42°C for 1 h with 1 g of total RNA in 0.1 mM DTT, and 50
M downstream primer after an initial incubation at 65°C for
10 min. Following denaturation at 95°C for 5 min, cDNA was
used as template to run PCR in the presence of Taq buffer,
upstream primer and Taq polymerase. The PCR protocol was
as follows: initial denaturation at 95°C for 5 min, 44 cycles
of 94°C for 1 min, 58°C for 1 min, 72°C for 1.5 min, with a
ﬁnal 5 min extension step at 72°C. The ORFK9 primers were
used in RT-PCR. To ensure that the samples were not contami-
nated with DNA, they were treated with RNAase-free DNAase
before performing RT-PCR.
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Sequence analysis
The KS330233 PCR product was cloned into the pCR 2.1 vector
(Invitrogen, San Diego, CA, USA) and sequenced with the
Sequenase Version 2.0 Sequencing Kit (Amersham Life
Science, Cleveland, OH, USA) according to the manufac-
turer’s instructions, and developed on X-ray ﬁlm.
Data were analyzed using the DNAsis program (Hitachi,
San Bruno, CA, USA), and compared with the GenBank
library data for HHV-8. For comparison we used two HHV-
8-containing cell lines, KS-1 and BC-1.13
Results
In this study, BM biopsy samples from patients with MM (n =
21), MGUS (n = 2), plasmacytoma (n = 1), and other hematol-
ogical disorders (n = 6), in addition to ﬁve healthy control
subjects, were evaluated for the presence of HHV-8. An
ampliﬁed product speciﬁc for KS330233 primers was observed
in 17 of 21 MM patients. Speciﬁcally, four of the six pre-
viously treated patients, and 13 of the 15 newly diagnosed
MM samples revealed viral presence (Figures 1 and 2) (Table
1). Results with three sets of primers (ORF26, ORFK9, and
Figure 1 Detection of KSHV gene sequences in DNA isolated from
bone marrow core biopsy of patients (upper lane: MM 3, 7, 8 and
10, and extramedullary plasmacytoma (EMP)), normal controls (lower
lane) and as a positive control KS-1 cell line by DNA-PCR using
ORF26 (KS330233) and beta-actin primers.
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Figure 2 DNA-PCR ampliﬁcation results on DNA samples
obtained from BM core biopsy from patients with MM (MM 11, 16,
17, 18 and 6; MGUS: MM 12, 19, 5 and 20), other hematological
disorders such as ITP, CML and lymphoma and DNA from KS-1 cell
line (positive control) using the vIRF primer (ORF K9) (upper lane) and
beta actin control (lower lane).
Table 1 Patient characteristics and the results of the DNA PCR with three pairs of primers
Patient No. Stage Age M type Year of dx KS330233 v IRF v IL-8R
(ORF26) (ORF K9) (ORF74)
Previously treated patients
1 IA 55 Lambda 1996 + + +
2 IIA 54 IgA lambda 1996 − ND ND
3 IIIB 58 IgG lambda 1998 + + ND
4 IIIA 47 IgG kappa 1996 + + +
5 IIIA 50 Kappa 1998 − − ND
6 IIIA 46 IgG 1999 + + ND
Untreated patients
7 IIA 65 IgG kappa 1998 + + +
8 IIB 72 IgA 1998 + + +
9 66 Plasmacytoma 1998 − − −
10 IIIA 56 IgG 1998 − − −
11 MGUS 43 IgG kappa 1998 − − −
12 MGUS 60 IgG 1998 − − ND
13 IIIA 78 IgG 1998 + + +
14 IIA 62 Kappa 1998 + + +
15 IIIB 58 IgA 1998 + + +
16 IIIA 38 Lambda 1998 + + −
17 IIA 70 IgA kappa 1999 + + +
18 IIA 51 IgG lambda 1999 + + +
19 IIA 69 IgG kappa 1999 + + +
20 IIA 66 IgG lambda 1999 + + +
21 IIIB 79 IgG 1998 + + ND
22 IIIA 71 IgG kappa 2000 ND + ND
23 IIA 50 Lambda 2000 ND + ND
24 IA 61 Lambda 1998 ND + ND
ND, not done.
ORF74) were in agreement as shown in Figure 3 and Table
1. Fourteen of the 29 samples including patients with plasma
cell disorders, and controls were independently analyzed in
Turkey. These analyses were done blindly and results were
completely in agreement with the results obtained in the US
Laboratory (Figure 4). Interestingly, the MM patient (patient 2)
who was in remission following autologous PBSCT showed
the absence of the virus. In addition, using these same three
sets of HHV-8 primers, no ampliﬁed product was obtained
from the patients with CML, ITP, lymphoma, and polyclonal
gammopathy (Figure 2). BM biopsy samples from the ﬁve nor-
mal subjects were also negative for the presence of HHV-8 in
both laboratories (Figures 1 and 4).
Figure 3 Comparison of three different primers: ORF 74 (vIL-8R),
ORFK9 (vIRF) and ORF 26 (KS330233) on the same samples (MM 13,
14, 4 and 15), negative and positive controls.
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Figure 4 DNA-PCR ampliﬁcation results on samples from patients
with MM (MM 1, 7, 8, 12, 16, 22, 23, 24); EMP and ﬁve normal
controls performed in an independent laboratory in Turkey using the
vIRF(ORFK9) and hMLH1(human mismatch repair gene) primers.
RT-PCR results
As demonstrated by ampliﬁcation with beta actin primers,
intact RNA was obtained from seven individuals (Table 2).
Four patients with monoclonal gammopathies (myeloma, n =
3; MGUS, n = 1), and three controls were analyzed. Using
the ORFK9 primer pair, the two MM patients showing viral
RNA also contained HHV-8 DNA (Table 2). Importantly, in
two patients (MM and MGUS) without DNA evidence of
HHV-8, there was also no ampliﬁed product with RT-PCR. In
the three normal subjects’ BM biopsies, no viral RNA was
found consistent with the DNA results.
Leukemia
Table 2 DNA and RT-PCR results using primer ORFK9 (vIRF)
Patient No. DNA-PCR RT-PCR
1 (MM) + +
8 (MM) + +
10 (MM) − −
12 (MGUS) − −
Control 1 − −
Control 2 − −
Control 3 − −
HHV-8 strain
Sequence analysis of ORF26 showed an HHV-8 strain pattern
consistent with a C3 subtype (Table 3) which has also been
found in MM patients from the United States.14
Discussion
Following the detection of HHV-8 in Kaposi’s sarcoma, its
association with AIDS-related body cavity-based lymphoma,
and multicentric Castleman’s disease has been reported.15,16
Since the initial observation demonstrating HHV-8 in nonma-
ligant stromal cells from patients with MM,3 conﬂicting reports
have been published.3–7,10,11,16–24 The HHV-8 genome enco-
des homologues of IL-6, IL-8R, viral interferon regulatory fac-
tor (vIRF), macrophage inﬂammatory proteins, bcl-2, and
cyclin D1.25 These molecules may be involved in both pro-
moting HHV-8 infection as well as directly or indirectly con-
tributing to malignant transformation and growth. Since HHV-
8 infects the supportive nonmalignant cells in the myeloma
bone marrow, the role of this virus is probably due to an
indirect inﬂuence in this malignant disease.
This study provides further evidence for the presence of this
virus in myeloma patients from another part of the world, sup-
porting its importance in myeloma pathogenesis. In this study,
we observed HHV-8 presence in 17 of the 21 Turkish patients
with MM. In contrast, none of the healthy subjects or patients
with other hematological disorders showed the presence of
HHV-8. Patients with solitary plasmacytoma (uninvolved
marrow) or MGUS also did not show evidence of the virus in
this study. One of the treated MM patients in this study with-
out HHV-8 was observed in a patient in remission following
autologous PBSCT. This type of treatment may reduce the viral
load below the sensitivity of this PCR assay. The inability to
detect virus following PBSCT was reported previously and was
regarded as evidence against the role of the virus in
MM.18,23,26 However, as demonstrated in this study, the lack
of detectable HHV-8 in this group of patients may not be
uncommon, especially in responding patients. In addition, the
absence of the virus in circulating cells is not sufﬁcient to rule
out the presence of HHV-8 in MM patients.11,24,26 In support
of this, the phenotype of cells examined for viral presence by
other groups differed from the cells that have been shown by
our group and others to contain HHV-8 in myeloma patients’
blood samples. Certainly, the frequency of virally infected cir-
culating cells may be less than the sensitivity of the method
of detection which can also vary greatly between laboratories.
Thirteen of the 15 previously untreated MM patients demon-
strated the presence of the virus. BM biopsy material was
essential for the demonstration of the virus. In contrast, BM
aspirates showed viral presence in only one sample in this
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Table 3 Sequence from 233 base pair fragment within ORF26
DNA Country Dx 475899 595 614 621 631 632 647 653 654 664 668 688 691 705 719 731 738 750 756 757 798 47788 Sub-group
source
Chang et al KS C G A C C C T C G G A T G C C A A A T C T G A
KS USA KS C C G A A A
KS-1 C-L A T T A C B
BC-1 C-L C T G A A A
MM USA MM A T T G C C3
MM 1 TR MM A T T T G C C C3
MM 4 TR MM A T T C G C C3
MM 7 TR MM A T T G C C3
MM 18 TR MM A T T G C C3
MM 19 TR MM A T T G C C3
Tr, Turkish.
study (data not shown) consistent with our previous ﬁndings
in US MM specimens.3 Since fresh BM aspirate is likely to
contain a lower proportion of dendritic cells than biopsy
material, a reduced ability to detect HHV-8 in these samples
is not surprising.17
Previous reports on the presence of HHV-8 in MM have
yielded conﬂicting results. Investigators have focused on the
detection of molecular evidence in a variety of tissues, includ-
ing BM aspiration or biopsy material, cultured dendritic cells
from leukapheresis products or BM samples.3–11,17,18,23–30
Others searched for serological evidence by antibodies against
the virus.19–22 All of these studies have been reviewed
recently.17,23 The most frequent method used in the studies
that failed to demonstrate viral presence in MM were PCR
assays with peripheral blood dendritic cells obtained after
long-term culture.23,24,26 The types of cells obtained in these
negative studies were highly variable, and contained different
cell populations than those studies showing HHV-8 in these
patients.3,7 In addition, the PCR assays including the types of
primers and positive and negative controls for detecting HHV-
8 were highly variable in these studies.22–24,27 Other groups
from the United States and Europe have identiﬁed HHV-8
DNA and RNA in MM patients consistent with this study.3–5,7
With an attempt to eliminate this uncertainty, we used the
same primer sets in two independent laboratories in a blind
fashion, and the results were completely concordant. In
addition, the presence of the same strain, C3, in both US and
Turkish myeloma patients further supports the presence of a
speciﬁc HHV-8 subtype in this B cell malignancy.14
In conclusion, this study demonstrates the frequent pres-
ence of HHV-8, conﬁrmed by two independent laboratories,
in MM patients with a speciﬁc viral strain in another geo-
graphic location; and, thus, provides further support for the
important role of this type of HHV-8 in the pathogenesis of
multiple myeloma.
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